CL2022001724A1 - Método y aplicación de preparación de compuesto como agente de degradación de proteínas - Google Patents
Método y aplicación de preparación de compuesto como agente de degradación de proteínasInfo
- Publication number
- CL2022001724A1 CL2022001724A1 CL2022001724A CL2022001724A CL2022001724A1 CL 2022001724 A1 CL2022001724 A1 CL 2022001724A1 CL 2022001724 A CL2022001724 A CL 2022001724A CL 2022001724 A CL2022001724 A CL 2022001724A CL 2022001724 A1 CL2022001724 A1 CL 2022001724A1
- Authority
- CL
- Chile
- Prior art keywords
- compound
- application
- preparation
- protein degradation
- degradation agent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911342649 | 2019-12-23 | ||
| CN202010200682 | 2020-03-20 | ||
| CN202010496353 | 2020-06-03 | ||
| CN202011486334 | 2020-12-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022001724A1 true CL2022001724A1 (es) | 2023-02-24 |
Family
ID=76573691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022001724A CL2022001724A1 (es) | 2019-12-23 | 2022-06-22 | Método y aplicación de preparación de compuesto como agente de degradación de proteínas |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US12441706B2 (enExample) |
| EP (1) | EP4083020A4 (enExample) |
| JP (1) | JP7791087B2 (enExample) |
| KR (1) | KR20220120629A (enExample) |
| CN (2) | CN113087704B (enExample) |
| AU (1) | AU2020414151A1 (enExample) |
| BR (1) | BR112022012385A2 (enExample) |
| CA (1) | CA3162523A1 (enExample) |
| CL (1) | CL2022001724A1 (enExample) |
| CO (1) | CO2022010305A2 (enExample) |
| EC (1) | ECSP22056811A (enExample) |
| IL (1) | IL294225B2 (enExample) |
| JO (1) | JOP20220159A1 (enExample) |
| MX (1) | MX2022007885A (enExample) |
| PE (1) | PE20230114A1 (enExample) |
| PH (1) | PH12022551571A1 (enExample) |
| TW (1) | TWI755992B (enExample) |
| WO (1) | WO2021129653A1 (enExample) |
| ZA (1) | ZA202208051B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL319363A (en) | 2017-01-31 | 2025-05-01 | Arvinas Operations Inc | Cervalon ligands and bifunctional compounds containing them |
| WO2021127443A1 (en) | 2019-12-19 | 2021-06-24 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| CN115996918A (zh) | 2020-05-09 | 2023-04-21 | 阿尔维纳斯运营股份有限公司 | 制造双官能团化合物的方法、双官能团化合物的超纯形式以及包括所述双官能团化合物的剂型 |
| KR20230024328A (ko) | 2020-06-12 | 2023-02-20 | 상하이 제민케어 파마슈티칼스 컴퍼니 리미티드 | 프탈라지논 화합물, 이의 제조 방법 및 이의 의학적 용도 |
| WO2022047145A1 (en) | 2020-08-28 | 2022-03-03 | Arvinas Operations, Inc. | Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| IL301690A (en) * | 2020-10-16 | 2023-05-01 | Dana Farber Cancer Inst Inc | Piperidinyl small molecule degraders of helios and methods of use |
| CA3217792A1 (en) | 2021-05-07 | 2022-11-10 | Kymera Therapeutics, Inc | Cdk2 degraders and uses thereof |
| TW202317546A (zh) | 2021-07-09 | 2023-05-01 | 美商普萊克斯姆公司 | 調節ikzf2之芳基化合物及醫藥組合物 |
| WO2024002205A1 (en) * | 2022-06-30 | 2024-01-04 | Anhorn Medicines Co., Ltd. | Bifunctional compound and pharmaceutical composition comprising the bifunctional compound, and method for treating androgen receptor related disease by using the same |
| CN119948021A (zh) * | 2022-07-15 | 2025-05-06 | 西藏海思科制药有限公司 | 一种含氮杂环衍生物及其组合物和药学上的应用 |
| EP4584258A1 (en) | 2022-09-07 | 2025-07-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
| AU2024392985A1 (en) | 2023-12-08 | 2026-06-04 | Arvinas Operations, Inc. | Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6245804B1 (en) | 1997-05-30 | 2001-06-12 | Schering Aktiengesellschaft | Nonsteroidal gestagens |
| US20180228907A1 (en) * | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| US20160058872A1 (en) | 2014-04-14 | 2016-03-03 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| EP4649963A3 (en) | 2014-04-14 | 2026-05-13 | Arvinas Operations, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| JP6817962B2 (ja) | 2015-01-20 | 2021-01-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| RU2689988C2 (ru) | 2015-04-21 | 2019-05-30 | Джи Ти Икс, ИНК. | Селективные лиганды-разрушители андрогенных рецепторов (sard) и способы их применения |
| CA2988414C (en) | 2015-06-04 | 2023-09-26 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| WO2017007612A1 (en) | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| SI3526202T1 (sl) * | 2016-10-11 | 2025-04-30 | Arvinas Operations, Inc. | Spojine in postopki za ciljno razgradnjo androgenskih receptorjev |
| AU2017363257B2 (en) * | 2016-11-22 | 2021-08-19 | Dana-Farber Cancer Institute, Inc. | Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use |
| US10842878B2 (en) | 2016-11-22 | 2020-11-24 | Dana-Farber Cancer Institute, Inc. | Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use |
| IL319363A (en) | 2017-01-31 | 2025-05-01 | Arvinas Operations Inc | Cervalon ligands and bifunctional compounds containing them |
| CN110194762B (zh) | 2018-02-27 | 2021-09-10 | 中国科学院上海药物研究所 | 酞嗪酮类衍生物、其制备方法和用途 |
| CN112390852B (zh) | 2019-08-14 | 2022-10-18 | 上海济煜医药科技有限公司 | 作为蛋白降解剂的化合物及其制备方法和应用 |
| CN112457367B (zh) | 2019-09-06 | 2022-08-23 | 上海济煜医药科技有限公司 | 作为蛋白降解剂的连环类化合物及其制备方法和应用 |
| CN118085015A (zh) | 2019-09-06 | 2024-05-28 | 江西济民可信集团有限公司 | 作为蛋白降解剂的并环类化合物及其制备方法和用途 |
| CN112574278B (zh) | 2019-09-29 | 2024-08-23 | 江西济民可信集团有限公司 | 作为蛋白降解剂杂环类化合物及其制备方法和医药应用 |
| CN113582974B (zh) | 2020-04-30 | 2022-05-17 | 江西济民可信集团有限公司 | 一类作为蛋白降解剂的化合物及其制备方法和医药用途 |
| KR20230024328A (ko) | 2020-06-12 | 2023-02-20 | 상하이 제민케어 파마슈티칼스 컴퍼니 리미티드 | 프탈라지논 화합물, 이의 제조 방법 및 이의 의학적 용도 |
-
2020
- 2020-12-23 AU AU2020414151A patent/AU2020414151A1/en active Pending
- 2020-12-23 MX MX2022007885A patent/MX2022007885A/es unknown
- 2020-12-23 US US17/788,154 patent/US12441706B2/en active Active
- 2020-12-23 CN CN202011545626.2A patent/CN113087704B/zh active Active
- 2020-12-23 KR KR1020227025429A patent/KR20220120629A/ko active Pending
- 2020-12-23 WO PCT/CN2020/138572 patent/WO2021129653A1/zh not_active Ceased
- 2020-12-23 PH PH1/2022/551571A patent/PH12022551571A1/en unknown
- 2020-12-23 TW TW109145818A patent/TWI755992B/zh active
- 2020-12-23 PE PE2022001313A patent/PE20230114A1/es unknown
- 2020-12-23 EP EP20908128.0A patent/EP4083020A4/en active Pending
- 2020-12-23 BR BR112022012385A patent/BR112022012385A2/pt unknown
- 2020-12-23 CA CA3162523A patent/CA3162523A1/en active Pending
- 2020-12-23 CN CN202080087926.2A patent/CN114829342A/zh active Pending
- 2020-12-23 IL IL294225A patent/IL294225B2/en unknown
- 2020-12-23 JP JP2022539058A patent/JP7791087B2/ja active Active
-
2022
- 2022-06-20 JO JOP/2022/0159A patent/JOP20220159A1/ar unknown
- 2022-06-22 CL CL2022001724A patent/CL2022001724A1/es unknown
- 2022-07-19 ZA ZA2022/08051A patent/ZA202208051B/en unknown
- 2022-07-20 EC ECSENADI202256811A patent/ECSP22056811A/es unknown
- 2022-07-21 CO CONC2022/0010305A patent/CO2022010305A2/es unknown
-
2025
- 2025-08-15 US US19/301,909 patent/US20250376463A1/en not_active Abandoned
-
2026
- 2026-03-02 US US19/553,703 patent/US20260193233A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PE20230114A1 (es) | 2023-01-27 |
| JOP20220159A1 (ar) | 2022-06-20 |
| PH12022551571A1 (en) | 2023-11-20 |
| IL294225B1 (en) | 2026-02-01 |
| WO2021129653A1 (zh) | 2021-07-01 |
| AU2020414151A1 (en) | 2022-08-25 |
| JP2023508097A (ja) | 2023-02-28 |
| CA3162523A1 (en) | 2021-07-01 |
| US20230111119A1 (en) | 2023-04-13 |
| BR112022012385A2 (pt) | 2022-08-30 |
| ZA202208051B (en) | 2023-11-29 |
| US12441706B2 (en) | 2025-10-14 |
| CN114829342A (zh) | 2022-07-29 |
| TWI755992B (zh) | 2022-02-21 |
| MX2022007885A (es) | 2022-09-19 |
| IL294225B2 (en) | 2026-06-01 |
| US20250376463A1 (en) | 2025-12-11 |
| CN113087704A (zh) | 2021-07-09 |
| US20260193233A1 (en) | 2026-07-09 |
| KR20220120629A (ko) | 2022-08-30 |
| TW202128662A (zh) | 2021-08-01 |
| JP7791087B2 (ja) | 2025-12-23 |
| ECSP22056811A (es) | 2022-12-30 |
| IL294225A (en) | 2022-08-01 |
| EP4083020A4 (en) | 2024-01-24 |
| EP4083020A1 (en) | 2022-11-02 |
| CO2022010305A2 (es) | 2022-08-09 |
| CN113087704B (zh) | 2023-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP22056811A (es) | Método y aplicación de preparación de compuesto como agente de degradación de proteínas | |
| CO2022017802A2 (es) | Compuesto de ftalazinona, y método de preparación y uso médico de este | |
| JOP20220155A1 (ar) | مشتقات البيرازول مفيدة كعوامل مضادة للسرطان | |
| CL2020000886A1 (es) | Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih. | |
| CL2020001547A1 (es) | Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa. | |
| MX2022015026A (es) | Compuesto heteroaromatico de imidazol de cinco miembros y uso del mismo. | |
| CO2018003728A2 (es) | Moduladores del receptor x farnesoide | |
| SA520411222B1 (ar) | مركبات بوصفها معدلات لعامل باديء حقيقي النواة 2ب وتركيبات وطرق | |
| DOP2024000039A (es) | Derivados de quinolina como inhibidores de la integrina alfa4beta7 | |
| NI201700135A (es) | Derivados de ciclohexano sustituido con amido | |
| MX382520B (es) | Compuestos de pirimidinodiona contra estados cardiacos. | |
| ECSP17007208A (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
| BR112023020274A2 (pt) | Método de preparo de composto bicíclico e aplicação como agente antifúngico | |
| CY1124251T1 (el) | Παραγωγα καρβοξαμιδιου | |
| UY39625A (es) | Derivados tricíclicos útiles como inhibidores de parp7 | |
| MX2020003732A (es) | Derivado de anillo fusionado como inhibidor del receptor a2a. | |
| MX2025006990A (es) | Compuesto quimerico protac, metodo de preparacion del mismo y uso del mismo | |
| PH12019550154A1 (en) | Azetidine derivative | |
| PE20151300A1 (es) | Composicion antifungica topica para el tratamiento de onicomicosis | |
| MX2022005415A (es) | Compuesto de imidazolidinona, metodo de preparacion del mismo y uso del mismo. | |
| MX2022008016A (es) | Compuesto antagonista de pd-l1. | |
| MX2024001613A (es) | Derivado de oxaspiro, metodo de preparacion del mismo y uso del mismo. | |
| MX2020002512A (es) | Composicion fungicida y metodo para controlar enfermedades de cultivos. | |
| BR112017016393A2 (pt) | composições farmacêuticas estáveis compreendendo agente antibacteriano | |
| CY1123083T1 (el) | Παραγωγα βενζιμιδαζολιου ως διπλοι προσδετες υποδοχεων η1 ισταμινης και η4 ισταμινης |